NASDAQ:BIOS - BioScrip Stock Price, News, & Analysis

$2.22
+0.02 (+0.91 %)
(As of 06/16/2019 01:28 AM ET)
Today's Range
$2.17
Now: $2.22
$2.25
50-Day Range
$1.88
MA: $2.05
$2.23
52-Week Range
$1.56
Now: $2.22
$4.14
Volume575,952 shs
Average Volume681,748 shs
Market Capitalization$285.85 million
P/E RatioN/A
Dividend YieldN/A
Beta0.49
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. Read More…

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:BIOS
CUSIP09069N10
Phone720-697-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$708.90 million
Book Value($1.12) per share

Profitability

Net Income$-51,690,000.00

Miscellaneous

Employees2,043
Market Cap$285.85 million
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) posted its quarterly earnings data on Thursday, May, 2nd. The company reported ($0.10) EPS for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.01. The business earned $178.96 million during the quarter, compared to analysts' expectations of $179.23 million. The firm's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.12) earnings per share. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for BioScrip.

What price target have analysts set for BIOS?

4 equities research analysts have issued 1 year price objectives for BioScrip's stock. Their forecasts range from $2.51 to $10.00. On average, they anticipate BioScrip's stock price to reach $5.0025 in the next twelve months. This suggests a possible upside of 125.3% from the stock's current price. View Analyst Price Targets for BioScrip.

What is the consensus analysts' recommendation for BioScrip?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip.

What are Wall Street analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:
  • 1. Barrington Research analysts commented, "We think they should have held one given that management is currently engaged in selling BIOS investors on the benefits of the pending Option Care transaction." (5/3/2019)
  • 2. According to Zacks Investment Research, "In the last-reported quarter, BioScrip's revenues getting affected by the impact of higher core product mix, including the impact of contract changes with UnitedHealthcare worries us. However, we are encouraged by the company’s progress in the third quarter, courtesy of its new multi-faceted CORE plan to improve its financial position. The company also expects to earn core revenues at Home Solutions and witness continued core growth. The company also took certain rigorous steps to revitalize its sales force in the reported quarter. These developments should further drive business growth in 2018. Overall,  BioScrip has outperformed its industry in the past six months." (1/3/2019)

Has BioScrip been receiving favorable news coverage?

Media headlines about BIOS stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BioScrip earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for BioScrip.

Are investors shorting BioScrip?

BioScrip saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 10,563,181 shares, an increase of 19.7% from the April 15th total of 8,822,312 shares. Based on an average daily trading volume, of 1,676,330 shares, the short-interest ratio is presently 6.3 days. Currently, 8.3% of the shares of the stock are short sold. View BioScrip's Current Options Chain.

Who are some of BioScrip's key competitors?

What other stocks do shareholders of BioScrip own?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:
  • Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 54)
  • Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
  • Ms. Harriet Booker, Sr. VP & COO (Age 52)
  • Mr. John McMahon, VP, Controller & Chief Accounting Officer (Age 54)
  • Mr. Vito Ponzio Jr., Chief Admin. Officer & Sr. VP (Age 64)

Who are BioScrip's major shareholders?

BioScrip's stock is owned by many different of institutional and retail investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (10.57%), BlackRock Inc. (6.96%), Gabelli Funds LLC (5.28%), FMR LLC (3.01%), Rothschild & Co. Asset Management US Inc. (2.96%) and Dimensional Fund Advisors LP (2.23%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Michael G Bronfein and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

Which major investors are selling BioScrip stock?

BIOS stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, BlackRock Inc., JPMorgan Chase & Co., Gabelli Funds LLC, Wells Fargo & Company MN, Morgan Stanley, FMR LLC and Diamond Hill Capital Management Inc.. View Insider Buying and Selling for BioScrip.

Which major investors are buying BioScrip stock?

BIOS stock was acquired by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., Essex Investment Management Co. LLC, SEI Investments Co, Dimensional Fund Advisors LP, Stephens Inc. AR, Raymond James & Associates, Prescott Group Capital Management L.L.C. and Geode Capital Management LLC. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf and Stephen Deitsch. View Insider Buying and Selling for BioScrip.

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $2.22.

How big of a company is BioScrip?

BioScrip has a market capitalization of $285.85 million and generates $708.90 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. BioScrip employs 2,043 workers across the globe.View Additional Information About BioScrip.

What is BioScrip's official website?

The official website for BioScrip is http://www.bioscrip.com/.

How can I contact BioScrip?

BioScrip's mailing address is 1600 BROADWAY SUITE 700, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]


MarketBeat Community Rating for BioScrip (NASDAQ BIOS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  506
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel